- Home
- RIGL vs BAND Comparison
RIGL vs BAND Comparison
Compare RIGL & BAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- BAND
- Stock Information
- Founded
- RIGL 1996
- BAND 2000
- Country
- RIGL United States
- BAND United States
- Employees
- RIGL N/A
- BAND N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- BAND Computer Software: Prepackaged Software
- Sector
- RIGL Health Care
- BAND Technology
- Exchange
- RIGL Nasdaq
- BAND Nasdaq
- Market Cap
- RIGL 335.5M
- BAND 431.0M
- IPO Year
- RIGL 2000
- BAND 2017
- Fundamental
- Price
- RIGL $38.85
- BAND $15.00
- Analyst Decision
- RIGL Buy
- BAND Buy
- Analyst Count
- RIGL 5
- BAND 6
- Target Price
- RIGL $38.20
- BAND $20.80
- AVG Volume (30 Days)
- RIGL 995.6K
- BAND 190.8K
- Earning Date
- RIGL 08-05-2025
- BAND 10-30-2025
- Dividend Yield
- RIGL N/A
- BAND N/A
- EPS Growth
- RIGL N/A
- BAND N/A
- EPS
- RIGL 5.43
- BAND N/A
- Revenue
- RIGL $267,921,000.00
- BAND $758,106,000.00
- Revenue This Year
- RIGL $59.93
- BAND $2.48
- Revenue Next Year
- RIGL N/A
- BAND $13.24
- P/E Ratio
- RIGL $7.15
- BAND N/A
- Revenue Growth
- RIGL 105.62
- BAND 14.51
- 52 Week Low
- RIGL $12.66
- BAND $11.33
- 52 Week High
- RIGL $43.72
- BAND $23.00
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- BAND 56.17
- Support Level
- RIGL $39.00
- BAND $14.21
- Resistance Level
- RIGL $42.08
- BAND $14.84
- Average True Range (ATR)
- RIGL 2.32
- BAND 0.49
- MACD
- RIGL -0.37
- BAND 0.15
- Stochastic Oscillator
- RIGL 53.26
- BAND 90.04
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About BAND Bandwidth Inc.
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of the company's revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.